Johns Hopkins Center for Psychedelic and Consciousness Research, founded in 2019 with $17 million in funding, conducts FDA-approved clinical trials on psilocybin for treating depression, addiction, and end-of-life distress. Its major research university affiliation, rigorous clinical trial protocols, and peer-reviewed publications in top medical journals place it at the highest standard of consciousness research.